By Fareed Sahloul
Oct 3, 2021, 1:39 PM
Word Count: 164
Ugur Sahin, co-founder and chief executive officer of BioNtech, told the Financial Times that while current variants of Covid-19, such as the contagious delta strain, were not different enough to undermine current vaccinations, new strains will emerge that can evade booster shots and the body’s immune defenses.
“This year [a different vaccine] is completely unneeded, but by mid-next year, it could be a different situation,” he said. “This is a continuous evolution, and that evolution has just started.”
BioNTech partnered with U.S. pharmaceuticals giant Pfizer Inc. to develop its Covid-19 vaccine. Last month, the companies submitted initial data to U.S. regulators about the use of the vaccine in children aged 5 to 11, one step closer to bringing shots to school-age kids.
© 2021 Bloomberg L.P.
Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]